ClinicalTrials.gg

Program

Leucovorin

Also written as “leucovorin”, “Folinic acid” and “FLOT Chemotherapy”.

Its studies are mostly in Colorectal Neoplasms · Neoplasms · Pancreatic Neoplasms · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 21 companies.

Furthest: phase 3, since May 9, 200734 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi50 open or runningphase 3since May 9, 2007May 9, 2007none ahead
AstraZeneca41 open or runningphase 2since Jul 17, 2003Jul 17, 2003Nov 9, 2027phase 2 · NCT07069712
Bristol-Myers Squibb40 open or runningphase 2since Jun 26, 2002Jun 26, 2002none ahead
Hoffmann-La Roche30 open or runningphase 2since Feb 26, 2010Feb 26, 2010none ahead
Pfizer21 open or runningphase 3since Sep 1, 2005Sep 1, 2005none ahead
3SBio11 open or runningphase 2since Jun 25, 2024Jun 25, 2024none ahead
AbbVie11 open or runningphase 2since Oct 25, 2023Oct 25, 2023Dec 2026phase 2 · NCT06107413
adherex-technologies-inc10 open or runningphase 2since Oct 27, 2010Oct 27, 2010none ahead
Aurobindo Pharma10 open or runningphase 2since Mar 28, 2014Mar 28, 2014none ahead
Cardiff Oncology10 open or runningphase 2since Feb 9, 2021Feb 9, 2021none ahead
Eli Lilly10 open or runningphase 2since Jul 3, 2012Jul 3, 2012none ahead
Ipsen10 open or runningphase 3since Sep 6, 2019Sep 6, 2019none ahead
Jiangsu HengRui Medicine11 open or runningphase 3since Feb 20, 2023Feb 20, 2023none ahead
leaf-vertical-inc10 open or runningphase 2since Jun 5, 2018Jun 5, 2018none ahead
Merck KGaA, Darmstadt, Germany10 open or runningphase 3since Dec 4, 2015Dec 4, 2015none ahead
Merrimack Pharmaceuticals10 open or runningphase 3since Dec 14, 2011Dec 14, 2011none ahead
Novartis10 open or runningphase 1since Jan 4, 2011Jan 4, 2011none ahead
oncolytics-biotech10 open or runningphase 1since Jan 7, 2011Jan 7, 2011none ahead
Swedish Orphan Biovitrum10 open or runningphase 2since Feb 14, 2006Feb 14, 2006none ahead
tty-biopharm10 open or runningphase 2since Apr 12, 2018Apr 12, 2018none ahead
wellstat-therapeutics10 open or runningphase 1since Sep 4, 2002Sep 4, 2002none ahead

Also a collaborator on its studies: Ono Pharmaceutical, parexel, Halozyme Therapeutics, biolinerx-ltd, axis-clinicals-limited and Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since Jun 26, 2002.

  1. Mar 28, 2014Aurobindo Pharma's first study: phase 2 study in Lymphoma, T-Cell, PeripheralNew to Aurobindo PharmaAurobindo Pharma · NCT02106650 · 36 enrolled · United States
  2. Dec 4, 2015Merck KGaA, Darmstadt, Germany's first study: phase 3 study in Neoplasm MetastasisNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT02625610 · 499 enrolled · United States, Australia, Brazil and more
  3. Jun 9, 2017Phase 2 study in Colorectal NeoplasmsBristol-Myers Squibb · NCT03184870 · 332 enrolled · United States, Australia, Belgium and more
  4. Sep 11, 2017Phase 2 study in Esophageal NeoplasmsHoffmann-La Roche · NCT03281369 · 219 enrolled · United States, Australia, Israel and more
  5. Nov 6, 2017Phase 2 study in Advanced Pancreatic CancerBristol-Myers Squibb · NCT03336216 · 205 enrolled · United States, Canada, Denmark and more
  6. Apr 12, 2018tty-biopharm's first study: phase 2 study in Colorectal NeoplasmsNew to tty-biopharmtty-biopharm · NCT03517618 · 41 enrolled · Taiwan
  7. Jun 5, 2018leaf-vertical-inc's first study: phase 2 study in Pancreatic NeoplasmsNew to leaf-vertical-incleaf-vertical-inc · NCT03607643 · 160 enrolled · United States
  8. Sep 6, 2019Ipsen's first study: phase 3 study in Metastatic Adenocarcinoma of the PancreasNew to IpsenIpsen · NCT04083235 · 770 enrolled · United States, Australia, Austria and more
  9. Oct 5, 2020Phase 3 study in NeoplasmsPfizer · NCT04607421 · 841 enrolled · United States, Argentina, Australia and more
  10. Feb 9, 2021Cardiff Oncology's first study: phase 2 study in Pancreatic Ductal AdenocarcinomaNew to Cardiff OncologyCardiff Oncology · NCT04752696 · 41 enrolled · United States
  11. Feb 20, 2023Jiangsu HengRui Medicine's first study: phase 3 study in First-line Treatment of Advanced Pancreatic CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05751850 · 778 planned · China
  12. Oct 25, 2023AbbVie's first study: phase 2 study in NeoplasmsNew to AbbVieAbbVie · NCT06107413 · 280 enrolled · United States, Belgium, Germany and more
  13. Jun 25, 20243SBio's first study: phase 2 study in Colorectal NeoplasmsNew to 3SBio3SBio · NCT06493760 · 130 planned · China
  14. Jun 24, 2025Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712 · 100 planned · United States, Canada, China and more

Ahead

  1. Dec 2026Primary completion: phase 2 study in NeoplasmsAbbVie · NCT06107413
  2. Nov 9, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 34 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07069712Stomach Neoplasms · United States, Canada, China and more2RecruitingAstraZenecaNov 9, 2027100
NCT06493760Colorectal Neoplasms · China2Recruiting3SBioJun 2025130
NCT06107413Neoplasms · United States, Belgium, Germany and more2Active, not recruitingAbbVieDec 2026280
NCT05751850First-line Treatment of Advanced Pancreatic Cancer · China3RecruitingJiangsu HengRui MedicineDec 30, 2024778
NCT04752696Pancreatic Ductal Adenocarcinoma · United States2TerminatedCardiff OncologyDec 24, 202441
NCT04607421Neoplasms · United States, Argentina, Australia and more3Active, not recruitingPfizerMar 1, 2025841
NCT04083235Metastatic Adenocarcinoma of the Pancreas · United States, Australia, Austria and more3CompletedIpsenJul 23, 2022770
NCT03607643Pancreatic Neoplasms · United States2UNKNOWNleaf-vertical-incJun 30, 2020160
NCT03517618Colorectal Neoplasms · Taiwan2Completedtty-biopharmJun 18, 201541
NCT03336216Advanced Pancreatic Cancer · United States, Canada, Denmark and more2CompletedBristol-Myers SquibbJun 1, 2023205
NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more2TerminatedHoffmann-La RocheOct 9, 2025219
NCT03184870Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedBristol-Myers SquibbApr 6, 2023332
NCT02625610Neoplasm Metastasis · United States, Australia, Brazil and more3CompletedMerck KGaA, Darmstadt, GermanySep 13, 2019499
NCT02106650Lymphoma, T-Cell, Peripheral · United States2CompletedAurobindo PharmaOct 201836
NCT01930552Neoplasms · China1CompletedSanofiDec 201420
NCT01634555Solid Tumors · United States2CompletedEli LillyAug 201329
NCT01494506Pancreatic Neoplasms · United States, Argentina, Australia and more3CompletedMerrimack PharmaceuticalsFeb 2014417
NCT01274624Neoplasms · United States1Completedoncolytics-biotechFeb 201836
NCT01271166Neoplasms · Australia1TerminatedNovartisAug 200910
NCT01231802Breast Neoplasms · United States, Russian Federation2UNKNOWNadherex-technologies-incAug 2012140
NCT01227707Colorectal Neoplasms · Italy2CompletedHoffmann-La RocheAug 201043
NCT01077739Colorectal Neoplasms · Belgium2CompletedHoffmann-La RocheJan 201275
NCT01046864Pyloric Stenosis, Hypertrophic · United States, Canada, France1CompletedBristol-Myers SquibbJun 201449
NCT00782041Uterine Neoplasms · Thailand2TerminatedSanofiAug 200311
NCT00559455Carcinoma, Hepatocellular · Korea, Republic of2CompletedSanofiJan 201038
NCT00499850Adenocarcinoma · Australia1CompletedSanofiJun 200618
NCT00471965Carcinoma, Hepatocellular · China, Korea, Republic of, Taiwan and more3CompletedSanofiMar 2010371
NCT00291785Colorectal Neoplasms · Italy2CompletedSwedish Orphan BiovitrumAug 200748
NCT00237900Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC · Finland2TerminatedAstraZeneca34
NCT00233623Colorectal Neoplasms · Italy2WithdrawnAstraZenecaJan 2006190
NCT00143403Colorectal Neoplasms · Belgium, Denmark, France and more3CompletedPfizerFeb 2008321
NCT00065117Colorectal Neoplasms · United States2TerminatedAstraZenecaFeb 2004180
NCT00044785Colorectal Neoplasms · United States1Terminatedwellstat-therapeutics24
NCT00040391Colorectal Neoplasms · United States2TerminatedBristol-Myers Squibb

How it is read

Names in the registry

  • “Leucovorin”, 18 entries
  • “leucovorin”, 4 entries
  • “Folinic acid”, 3 entries
  • “FLOT Chemotherapy”, 1 entry
  • “Folinic Acid”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.